Navigation Links
Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:12/8/2009

hood of relapse," commented Professor D. Hoelzer, chairman of the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL). "These data suggest that blinatumomab is very active and has the potential to be an effective consolidation therapy."

"The data from this completed phase 2 study confirm the high response rate reported earlier this year from the ongoing study," commented Dr. Jan Fagerberg, Micromet's Chief Medical Officer. "We expect that the positive risk/benefit profile of blinatumomab in ALL will pave the way for a pivotal trial and a fast track to market in this indication."

(1) Topp, M. et al. (2009). Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting, abstract no. 840

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
4. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
5. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
6. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
7. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
8. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
9. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
10. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
11. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Varian Medical Systems (NYSE: VAR) today broke ground on new ... City manufacturing facility and allow for the consolidation ... to ultimately create 1,000 new full time jobs in ... " Utah is home to hardworking people ... be credited with Varian,s success in the manufacturing of our ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014   Los ... now offers AcceleDent® Aura to patients who want to ... orthodontic care available at the OrthoSpaceship, all patients have ... better-looking teeth. This system can be used by most ... their rate of progress by using the AcceleDent® Aura ...
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
Breaking Medicine Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 4Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3
... Nov. 23 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... U.S. Food and Drug Administration (FDA) on January 20, 2010 ... Application (NDA) for Intermezzo ® (zolpidem tartrate ... by Transcept on October 28, 2009, indicated that the FDA ...
... , ORANGE COUNTY, Calif., Nov. 23 ... a leading developer, manufacturer, and marketer of products that ... that Allan Harris, Beckman Coulter,s vice president of strategy, ... Wednesday, December 2, 2009 at 12:00 p.m. (ET). , ...
Cached Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2
(Date:8/27/2014)... Aeroflow Healthcare has announced it ... of a strategic expansion of its durable medical ... ownership of new businesses through additional resources and ... , Last week, the company announced that it ... increase service in the High Point/Greensboro/Winston-Salem area. This ...
(Date:8/27/2014)... A St. Louis law firm that represents ... that the C.R. Bard multidistrict litigation (MDL), an MDL ... lawsuits, recently filed a new pretrial order (PTO) on ... discovery process, and more specifically to the management of ... & Lowe is a law firm practicing defective medical ...
(Date:8/27/2014)... New York (PRWEB) August 28, 2014 ... Market Research "Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... valued at USD 218.5 million in 2013 and is ... 2014 to 2020, to reach an estimated value of ...
(Date:8/27/2014)... August 28, 2014 Recently, BambooIndustry.com, an innovative ... has announced that new bamboo panels are now ... providing deep discounts for clients worldwide. All people that place ... discounted rate, from 10 to 30 percent off. , ... new panels. “At the moment, all our new and old ...
(Date:8/27/2014)... August 28, 2014 DiaSorin has announced ... of 1,25 Dihydroxyvitamin D,” will feature guest speaker Dr. ... George Institute for Health and Healing Integrative Medicine. Dr. ... Penny George Institute for Health and Healing and as ... Care, Minneapolis, Minnesota. He also serves as a co-editor ...
Breaking Medicine News(10 mins):Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Carey Danis & Lowe Reports On New Court Order in C.R. Bard Transvaginal Mesh MDL 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3
... 2008 at 11:00 AM ET, LIVINGSTON, N.J., May ... recognized leader in advanced,injection technologies, today announced that the ... ended March 31, 2008 on Thursday,May 15, 2008., ... 2008, beginning,at 11:00 AM Eastern time, and invites all ...
... funding to PBTF Institute at Duke accelerates search for ... ... The Pediatric Brain,Tumor Foundation (PBTF) is giving an additional $6 million ... to $12 million., To view the Multimedia News Release, go ...
... for prehypertensive people in morning use, researchers report , , ... can control prehypertension, but only if it is taken ... taken every morning didn,t lower the blood pressure of ... C. Hermida reported Wednesday at the American Society of ...
... Del., May 14 AstraZeneca (NYSE:,AZN) today announced ... has,approved SEROQUEL(R) (quetiapine fumarate tablets) for the maintenance,treatment ... therapy to,lithium or divalproex. SEROQUEL is approved by ... also the only single agent approved by the ...
... AMRN ) today announced a private placement ... ("ADSs") with several new,institutional and accredited investors, and ... $60 million funded over two equal tranches., ... agreements for,gross proceeds of up to $56 million, ...
... Mass., and SYDNEY, Australia, May 14 /PRNewswire-FirstCall/,-- HeartWare Limited ... an investor presentation at the Seventh Annual JMP Securities ... Wednesday, May 21, 2008. The,conference is being held at ... webcast of the Company,s presentation at the conference will ...
Cached Medicine News:Health News:Milestone Scientific to Announce First Quarter 2008 Results on Thursday, May 15, 2008 2Health News:Video: Pediatric Brain Tumor Foundation Gives $6 Million Grant to Duke 2Health News:Aspirin at Bedtime Lowers Blood Pressure 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 3Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 4Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 5Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 6Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 7Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 8Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 9Health News:Amarin Announces Private Placement for up to $60 Million 2Health News:Amarin Announces Private Placement for up to $60 Million 3Health News:Amarin Announces Private Placement for up to $60 Million 4Health News:Amarin Announces Private Placement for up to $60 Million 5Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2
... a user friendly computerized medical record system ... and productivity of the practice as well ... documentation. It provides clinical templates for commonly ... It also contains an exhaustive database to ...
... GE Medical Systems Information ... see for yourself how ... Physician Office - Practice ... Manager) can simplify your ...
... 2V slit lamp is ... lamp that is designed ... tower and has standard ... Revolutionary design provides increased ...
... ReSeeVit CR-DGi Retinal Camera System is an ... retinal segment images for documentation, diagnosis and ... CR-DGi retinal camera for optimal performance. We ... designed for anterior segment images. ReSeeVit is ...
Medicine Products: